EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

RegulatoryTryngolzaPositive

AI Analysis

Summary

Sobi announced that the European Medicines Agency has validated an indication extension application for Tryngolza (olezarsen) to treat adult patients with severe hypertriglyceridemia. This regulatory validation represents progress toward potential approval of the expanded indication in Europe.

Outcome Details

EMA validated indication extension application for Tryngolza for treatment of severe hypertriglyceridemia

Importance:6/10

Sentiment:

0.60

EMAindication extensionregulatory validationTryngolzaolezarsenhypertriglyceridemia

Related Companies

$SOBI

Read the original article

Published by PR Newswire Biotech on March 30, 2026 6:23 AM

Read Original